B01AC24 • ticagrelor • Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin
Ticagrelor is an antiplatelet medication used to prevent thrombotic events such as myocardial infarction or stroke in patients with acute coronary syndromes or a history of myocardial infarction. It works by reversibly inhibiting P2Y12 receptors on platelets, preventing platelet aggregation.
The medication is taken orally, usually twice daily, as directed by a doctor. It is important for patients to follow the prescribed dosage and not discontinue treatment without consulting their doctor.
Patients should be monitored for potential side effects, such as bleeding, shortness of breath, or dizziness. It is important to inform the doctor of any unusual symptoms or the use of other medications.
Common side effects include bleeding, shortness of breath, and dizziness. In rare cases, severe reactions such as major hemorrhages or bradycardia may occur. Patients should be informed of these risks before starting treatment.
Substance: ticagrelor
Date of last drug list: 01-05-2024
Commercial code: W70208022
Concentration: 60mg
Pharmaceutical form: tablets
Quantity: 180
Product type: generic
Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.
Manufacturer: SWYSSI AG - GERMANIA
Holder: SWYSSI AG - GERMANIA
Number: 15369/2024/22
Shelf life: 3 years